openPR Logo
Press release

Congestive Heart Failure (CHF) Treatment Devices Market To Witness Exponential Growth By 2027

01-18-2021 02:03 PM CET | Health & Medicine

Press release from: Allied Market Research

Congestive Heart Failure (CHF) Treatment Devices Market

Congestive Heart Failure (CHF) Treatment Devices Market

UPDATE AVAILABLE ON-DEMAND

Global Congestive Heart Failure (CHF) Treatment Devices Market would reach $14.8 billion by 2022, at a CAGR of 5.5% from 2016 to 2022, according to a new report published by Allied Market Research.Implantable cardioverter-defibrillator (ICDs) segment is expected to dominate the global CHF treatment devices market throughout the forecast period. North America is projected to continue its lead in terms of revenue, accounting for more than two-fifths share of the CHF treatment devices.

Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/663

The major factors boosting the market growth include the growing incidence of heart failures, technological advancements in CHF treatment devices, and increasing adoption rates for these devices. In addition, rising incidence of diabetes, atherosclerosis, strokes, hypertension, and others due to faulty lifestyle habits such as unhealthy dietary habits, lack of physical activity, and smoking, among others are the leading causes of congestive heart failure. Rising geriatric population base is expected to fuel the prevalence of congestive heart failures thereby augmenting the market growth. Presence of huge unmet medical needs and rising emphasis on early intervention and primary prevention of heart failures are also anticipated to drive the demand for these devices. However, high cost of these devices and unfavorable reimbursement scenario in the emerging countries are some of the factors that restrict the market growth.

Geographically, North America accounted for the majority of the share in the CHF treatment devices market in 2015, and is expected to maintain this lead throughout the forecast period. This was mainly attributed to the increasing incidence of heart failures, presence of highly sophisticated healthcare infrastructure, and adoption of advanced CHF treatment devices in the North American countries. However, Asia-Pacific is expected to be the fastest growing region throughout the analysis period, owing to ample growth opportunities in terms of unmet medical needs for the treatment of cardiac disorders in these regions.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/663

The Major Key Players Are:

• Abiomed, Inc.
• Berlin Heart GmbH
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• HeartWare International, Inc.
• Jarvik Heart, Inc.
• LivaNova PLC
• Medtronic plc
• ReliantHeart Inc.
• St. Jude Medical, Inc.

Key Findings of the CHF Market:

• In 2015, ICDs accounted for almost one-third of the overall market revenue, and is projected to grow at a CAGR of 4.8% during the forecast period.
• The VADs segment is likely to grow at a remarkable CAGR of 11.9%, owing to the innovation and miniaturization of devices.
• North America accounted for over 40% share of the global CHF treatment devices market in 2015.
• The U.S. is projected to maintain its lead in the CHF treatment devices market until 2022.
• China and Japan are the major shareholders in the Asia-Pacific region, jointly accounting for almost half of share in the Asia-Pacific market.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Congestive Heart Failure (CHF) Treatment Devices Market To Witness Exponential Growth By 2027 here

News-ID: 2226595 • Views:

More Releases from Allied Market Research

Converting Paper Market Poised for Remarkable Growth, to Surpass USD 545.9 Billion by 2033
Converting Paper Market Poised for Remarkable Growth, to Surpass USD 545.9 Billi …
The global converting paper market was valued at $341.9 billion in 2023 and is projected to reach $545.9 billion by 2033, growing at a CAGR of 4.8% from 2024 to 2033. This growth is fueled by the increasing demand for customized paper products across various industries, including packaging, publishing, and e-commerce. Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/A10550 Converting paper refers to the process of transforming raw paper
[2026] Trichlorosilane (TCS) Market Growing at a CAGR of 9.5% to 2033, Says AMR
[2026] Trichlorosilane (TCS) Market Growing at a CAGR of 9.5% to 2033, Says AMR
Trichlorosilane (SiHCl3) is a silicon-based chemical compound with the molecular formula SiHCl3. It is a key intermediate in the production of silicon-based materials and is primarily used to manufacture polysilicon, which is the main component in solar cells and semiconductor devices. TCS is produced by the hydrochlorination of silicon tetrachloride (SiCl4) or by the reaction of silicon with hydrogen chloride. The global trichlorosilane market size was valued at $5.4 billion
Insights into the Gallic Acid Market Growth, Global Industry Forecast, 2033
Insights into the Gallic Acid Market Growth, Global Industry Forecast, 2033
Gallic acid (C7H6O5), also known as 3,4,5-trihydroxybenzoic acid, is a naturally occurring phenolic acid found in many plants, fruits, and natural substances like tea, grapes, berries, and oak bark. It is a secondary plant metabolite that plays a key role in plant defense mechanisms. The global gallic acid market was valued at $81.0 million in 2023, and is projected to reach $137.5 million by 2033, growing at a CAGR of
[2026] Insights into Single Crystal Diamond Market Trend, Strategies, Growth Opportunities, 2033
[2026] Insights into Single Crystal Diamond Market Trend, Strategies, Growth Opp …
A single crystal diamond is a diamond with a continuous and uninterrupted crystal lattice structure, free of grain boundaries or polycrystalline defects. Unlike polycrystalline diamonds, which have multiple small crystals fused together, single crystal diamonds have a perfect, uniform atomic arrangement. The global single crystal diamond market was valued at $1.5 billion in 2023, and is projected to reach $2.4 billion by 2033, growing at a CAGR of 4.7% from

All 5 Releases


More Releases for CHF

MEYE Asset Management Secures CHF 48 Million Victory in Major International Disp …
ZURICH, Switzerland - March 26, 2026 - Swiss asset manager MEYE Asset Management has secured a decisive legal victory in a high-profile cross-border dispute against a German industrial and investment group, with a court awarding the firm CHF 48 million in damages. The case arose from a contractual disagreement linked to a structured investment transaction, where the German counterparty allegedly failed to meet several of its core obligations. According to sources
MEYE Asset Management Secures CHF 48 Million Victory in Major International Disp …
ZURICH, Switzerland - March 26, 2026 - Swiss asset manager MEYE Asset Management has secured a decisive legal victory in a high-profile cross-border dispute against a German industrial and investment group, with a court awarding the firm CHF 48 million in damages. The case arose from a contractual disagreement linked to a structured investment transaction, where the German counterparty allegedly failed to meet several of its core obligations. According to sources
Work-ID AG: Tackling the Skills Shortage with CHF 4 Million and Skills-Manager
Thalwil, June 25, 2025 - Work-ID AG has closed a successful CHF 4 million financing round. The Thalwil-based start-up is launching Skills-Manager, a tool that shows companies which people fit both professionally and personally. Selecting by age, appearance, or gender? That was yesterday. Skills are the hard currency for smart companies. Skills-Manager reveals who is a real fit With Skills-Manager, companies gain a tool to identify and leverage people's skills. They can
Global Congestive Heart Failure (CHF) Market Outlook 2025-2034: Trends, Innovati …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics. What Is the Congestive Heart Failure (CHF) Market Size and Projected Growth Rate? The market scope for congestive heart failure (CHF) has seen robust augmentation in the past few years. The growth metrics show a burgeoning move from $15.94 billion in 2024 to $17.10 billion in 2025 with a compound annual growth rate (CAGR)
Congestive Heart Failure (CHF) Treatment Devices Market Revenue Sizing Outlook A …
Allied Market Research added new research on Global Congestive Heart Failure (CHF) Treatment Devices Market- Global Opportunity Analysis and Industry Forecast, 2022-2030. The Congestive Heart Failure (CHF) Treatment Devices market explores comprehensive study on various segments like size, share, development, innovation, sales and overall growth of major players. The research is based on primary and secondary data sources and it consists both qualitative and quantitative detailing. Some of the key
Chronic Heart Failure (CHF) Drugs Industry Outlook and Forecast 2020-2025
This report also researches and evaluates the impact of Covid-19 outbreak on the Chronic Heart Failure (CHF) Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Chronic Heart Failure (CHF) Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). GLOBAL INFO RESEARCH has lately published a new report titled, *Global Chronic Heart Failure (CHF) Drugs Market 2020 by Manufacturers, Regions,